AbCellera Biologics Inc. (ABCL) Stock Analysis & Investment Frameworks
AbCellera Biologics Inc. (ABCL) stock analysis on Invetso. Review AbCellera Biologics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
AbCellera Biologics Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
AbCellera Biologics Inc. Key Financial Metrics
- Market Cap: $3.83B
- Revenue: $75.13M
- ROE: -17.49%
- ROIC: -14.95%
- Dividend Yield: N/A
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. Investment Frameworks
Invetso analyzes AbCellera Biologics Inc. (ABCL) across the following frameworks:
- AbCellera Biologics Inc. 10Y Growth Potential
- AbCellera Biologics Inc. Scenario Analysis
- AbCellera Biologics Inc. Risks & Opportunities
- AbCellera Biologics Inc. Economic Moat
- AbCellera Biologics Inc. Business Model
- AbCellera Biologics Inc. Management
- AbCellera Biologics Inc. SWOT Analysis
- AbCellera Biologics Inc. Porter's 5 Forces
- AbCellera Biologics Inc. PESTLE Analysis
- AbCellera Biologics Inc. ESG Analysis